Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men.
African American
Veterans Health Administration
active surveillance
clinical outcomes
intermediate-risk prostate cancer
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
revised:
26
05
2021
received:
16
03
2021
accepted:
21
06
2021
pubmed:
5
8
2021
medline:
11
3
2022
entrez:
4
8
2021
Statut:
ppublish
Résumé
The safety of active surveillance (AS) for African American men compared with non-Hispanic White (White) men with intermediate-risk prostate cancer is unclear. The authors identified patients with modified National Comprehensive Cancer Network favorable ("low-intermediate") and unfavorable ("high-intermediate") intermediate-risk prostate cancer diagnosed between 2001 and 2015 and initially managed with AS in the Veterans Health Administration database. They analyzed definitive treatment, disease progression, metastases, prostate cancer-specific mortality (PCSM), and all-cause mortality by using cumulative incidences and multivariable competing-risks (disease progression, metastasis, and PCSM) or Cox (all-cause mortality) regression. The cohort included 1007 men (African Americans, 330 [32.8%]; Whites, 677 [67.2%]) followed for a median of 7.7 years; 773 (76.8%) had low-intermediate-risk disease, and 234 (23.2%) had high-intermediate-risk disease. The 10-year cumulative incidences of definitive treatment were not significantly different (African Americans, 83.5%; 95% confidence interval [CI], 78.5%-88.7%; Whites, 80.6%; 95% CI, 76.6%-84.4%; P = .17). Among those with low-intermediate-risk disease, there were no significant differences in the 10-year cumulative incidences of disease progression (African Americans, 46.8%; 95% CI, 40.0%-53.3%; Whites, 46.9%; 95% CI, 42.1%-51.5%; P = .91), metastasis (African Americans, 7.1%; 95% CI, 3.7%-11.8%; Whites, 10.8%; 95% CI, 7.6%-14.6%; P = .17), or PCSM (African Americans, 3.8%; 95% CI, 1.6%-7.5%; Whites, 3.8%; 95% CI, 2.0%-6.3%; P = .69). In a multivariable regression including the entire cohort, African American race was not associated with increased risks of definitive treatment, disease progression, metastasis, PCSM, or all-cause mortality (all P > .30). Outcomes in the Veterans Affairs Health System were similar for African American and White men treated for low-intermediate-risk prostate cancer with AS.
Sections du résumé
BACKGROUND
The safety of active surveillance (AS) for African American men compared with non-Hispanic White (White) men with intermediate-risk prostate cancer is unclear.
METHODS
The authors identified patients with modified National Comprehensive Cancer Network favorable ("low-intermediate") and unfavorable ("high-intermediate") intermediate-risk prostate cancer diagnosed between 2001 and 2015 and initially managed with AS in the Veterans Health Administration database. They analyzed definitive treatment, disease progression, metastases, prostate cancer-specific mortality (PCSM), and all-cause mortality by using cumulative incidences and multivariable competing-risks (disease progression, metastasis, and PCSM) or Cox (all-cause mortality) regression.
RESULTS
The cohort included 1007 men (African Americans, 330 [32.8%]; Whites, 677 [67.2%]) followed for a median of 7.7 years; 773 (76.8%) had low-intermediate-risk disease, and 234 (23.2%) had high-intermediate-risk disease. The 10-year cumulative incidences of definitive treatment were not significantly different (African Americans, 83.5%; 95% confidence interval [CI], 78.5%-88.7%; Whites, 80.6%; 95% CI, 76.6%-84.4%; P = .17). Among those with low-intermediate-risk disease, there were no significant differences in the 10-year cumulative incidences of disease progression (African Americans, 46.8%; 95% CI, 40.0%-53.3%; Whites, 46.9%; 95% CI, 42.1%-51.5%; P = .91), metastasis (African Americans, 7.1%; 95% CI, 3.7%-11.8%; Whites, 10.8%; 95% CI, 7.6%-14.6%; P = .17), or PCSM (African Americans, 3.8%; 95% CI, 1.6%-7.5%; Whites, 3.8%; 95% CI, 2.0%-6.3%; P = .69). In a multivariable regression including the entire cohort, African American race was not associated with increased risks of definitive treatment, disease progression, metastasis, PCSM, or all-cause mortality (all P > .30).
CONCLUSIONS
Outcomes in the Veterans Affairs Health System were similar for African American and White men treated for low-intermediate-risk prostate cancer with AS.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
4403-4412Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR001443
Pays : United States
Organisme : Department of Defense
ID : W81XWH-17-PCRP-PRA
Informations de copyright
© 2021 American Cancer Society.
Références
Parikh RB, Robinson KW, Chhatre S, et al. Comparison by race of conservative management for low-risk and intermediate-risk prostate cancers in veterans from 2004 to 2018. JAMA Netw Open. 2020;3:e2018318.
Tosoian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016;13:205-215.
Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314:80-82.
Butler SS, Mahal BA, Lamba N, et al. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. Cancer. 2019;125:3164-3171.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer. Version 2.2021. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed May 26, 2021.
Huang FW, Mosquera JM, Garofalo A, et al. Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations. Cancer Discov. 2017;7:973-983.
Mahal BA, Alshalalfa M, Spratt DE, et al. Prostate cancer genomic-risk differences between African-American and White men across Gleason scores. Eur Urol. 2019;75:1038-1040.
Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer-specific mortality across Gleason scores in Black vs Nonblack Men. JAMA. 2018;320:2479-2481.
Smith ZL, Eggener SE, Murphy AB. African-American prostate cancer disparities. Curr Urol Rep. 2017;18:81.
Silberstein JL, Feibus AH, Maddox MM, et al. Active surveillance of prostate cancer in African American men. Urology. 2014;84:1255-1261.
Masic S, Washington SL III, Carroll PR. Management of intermediate-risk prostate cancer with active surveillance: never or sometimes? Curr Opin Urol. 2017;27:231-237.
Stolzenbach LF, Rosiello G, Pecoraro A, et al. Prostate cancer grade and stage misclassification in active surveillance candidates: Black versus White patients. J Natl Compr Canc Netw. 2020;18:1492-1499.
Meunier ME, Eyraud R, Sénéchal C, et al. Active surveillance for favorable risk prostate cancer in African Caribbean men: results of a prospective study. J Urol. 2017;197:1229-1236.
Yang DD, Mahal BA, Muralidhar V, et al. Risk of upgrading and upstaging among 10 000 patients with Gleason 3+4 favorable intermediate-risk prostate cancer. Eur Urol Focus. 2019;5:69-76.
Yang DD, Mahal BA, Muralidhar V, et al. Pathologic outcomes of Gleason 6 favorable intermediate-risk prostate cancer treated with radical prostatectomy: implications for active surveillance. Clin Genitourin Cancer. 2018;16:226-234.
Filson CP, Shelton JB, Tan H-J, et al. Expectant management of veterans with early-stage prostate cancer. Cancer. 2016;122:626-633.
Loeb S, Byrne N, Makarov DV, Lepor H, Walter D. Use of conservative management for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System from 2005-2015. JAMA. 2018;319:2231-2233.
Veterans Health Administration-About VHA US Department of Veterans Affairs. https://www.va.gov/health/aboutvha.asp. Accessed May 26, 2021.
Corporate Data Warehouse (CDW). US Department of Veterans Affairs. https://www.hsrd.research.va.gov/for_researchers/vinci/cdw.cfm. Accessed October 15, 2020.
Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173:1938-1942.
Yang DY, Monn MF, Kaimakliotis HZ, Cary KC, Cheng L, Koch MO. Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy. Urol Oncol. 2015;33:70.e9-70.e14.
Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology. 2008;72:396-400.
Deka R, Courtney PT, Parsons JK, et al. Association between African American race and clinical outcomes in men treated for low-risk prostate cancer with active surveillance. JAMA. 2020;324:1747-1754.
Karunamuni R, Nalawade V, Bruggeman A, et al. Automated text mining of prostate pathology reports extracted from an electronic medical system, using a rule-based approach. Int J Radiat Oncol Biol Phys. 2018;102:e271.
Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
Coogan PF, Castro-Webb N, Yu J, O'Connor GT, Palmer JR, Rosenberg L. Neighborhood and individual socioeconomic status and asthma incidence in African American women. Ethn Dis. 2016;26:113-122.
Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415-1424.
McKay RR, Sarkar RR, Kumar A, et al. Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration. Cancer. 2021;127:403-411.
Riviere P, Luterstein E, Kumar A, et al. Survival of African American and non-Hispanic White men with prostate cancer in an equal-access health care system. Cancer. 2020;126:1683-1690.
Dess RT, Hartman HE, Mahal BA, et al. Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 2019;5:975-983.
Musunuru HB, Yamamoto T, Klotz L, et al. Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience. J Urol. 2016;196:1651-1658.
Bul M, van den Bergh RC, Zhu X, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110:1672-1677.
Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J. Long-term results of active surveillance in the Goteborg randomized, population-based Prostate Cancer Screening Trial. Eur Urol. 2016;70:760-766.
Dall'Era MA, Klotz L. Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017;20:1-6.
Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016;14:19-30.
Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64:895-902.